CIDE A is a DFF45 inhibitable effector that promotes cell death and DNA fragmentation. CIDE A is expressed in many tissues.
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| Cat. #: | 152792 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Apoptosis and autophagy;Biochemistry;Cancer;Cell biology;Genetics;Metabolism;Tissue-specific biology |
| Application: | ELISA ; IHC ; WB |
| Target: | Cell Death-Inducing DFFA-Like Effector A (CIDE A) |
| Reactivity: | Human |
| Clone: | V62P1E3*B10 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | Cell death activator CIDE A, Cell Death Inducing DFFA Like Effector A, cell death inducing DNA fragmentation factor, alpha subunit like effector A, CIDE-A, CIDEA |
|---|---|
| Product description: | Apoptosis is related to many diseases and induced by a family of cell death receptors and their ligands. Cell death signals are transduced by death domain containing adapter molecules and members of the caspase family of proteases. These death signals finally cause the degradation of chromosomal DNA by activated DNase. DFF45/ICARD has been identified as inhibitor of caspase activated DNase DFF40/CAD. DFF45 related proteins CIDE A and CIDE B (for cell death inducing DFF like effector A and B) were recently identified. CIDE contains a new type of domain termed CIDE N, which has high homology with the regulatory domains of DFF45/ICAD and DFF40/CAD. Expression of CIDE A induces DNA fragmentation and activates apoptosis, which is inhibited by DFF45. CIDE A is a DFF45 inhibitable effector that promotes cell death and DNA fragmentation. CIDE A is expressed in many tissues. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | Ovalbumin-conjugated synthetic peptide- QAKGRFTCG |
| Myeloma used: | P3X63Ag8.653 |
| Target background: | Apoptosis is related to many diseases and induced by a family of cell death receptors and their ligands. Cell death signals are transduced by death domain containing adapter molecules and members of the caspase family of proteases. These death signals finally cause the degradation of chromosomal DNA by activated DNase. DFF45/ICARD has been identified as inhibitor of caspase activated DNase DFF40/CAD. DFF45 related proteins CIDE A and CIDE B (for cell death inducing DFF like effector A and B) were recently identified. CIDE contains a new type of domain termed CIDE N, which has high homology with the regulatory domains of DFF45/ICAD and DFF40/CAD. Expression of CIDE A induces DNA fragmentation and activates apoptosis, which is inhibited by DFF45. CIDE A is a DFF45 inhibitable effector that promotes cell death and DNA fragmentation. CIDE A is expressed in many tissues. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
The expression of brown fat-associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. The expression of brown fat associated proteins in colorectal cancer and the relationship of uncoupling protein 1 with prognosis. Alnabulsi et al. 2019. Int J Cancer. :. PMID: 30737786. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.